Establish HIV infection, treatment, and engineered B cell memory responses in the THX mouse model
NIAID - National Institute of Allergy and Infectious Diseases
About This Grant
PROJECT SUMMARY A functional cure for HIV that maintains lifelong suppression of viremia without antiretroviral therapy (ART) remains an urgent unmet need. Broadly neutralizing antibodies (bnAbs) can control HIV, but vaccines have failed to induce them because they require unusual structural features that are not readily generated by natural B cell maturation. Genome engineering now allows mature bnAb genes to be inserted into the immunoglobulin heavy chain (IgH) locus of primary B cells, where they function as antigen receptors capable of undergoing germinal center maturation and forming memory responses. In mice, IgH-reprogrammed B cells generate durable bnAb titers near therapeutic levels after vaccination. However, the in vivo behavior of genome-engineered human B cells has not been tested due to the lack of an appropriate model. The recently developed Truly Human Xenograft (THX) mouse supports robust antigen-dependent human B cell responses and thus provides a unique opportunity to establish a preclinical platform for engineered B cell therapies. In Specific Aim 1, we will determine whether IgH-reprogrammed human B cells can participate in germinal center reactions and generate memory and long-lived plasma cells following vaccination in THX mice. In Specific Aim 2, we will establish an HIV infection and treatment model in THX mice, adapting mucosal challenge, ART suppression, and analytical treatment interruption protocols to evaluate viral rebound and reservoir establishment. Completion of these aims will demonstrate feasibility of eliciting vaccine-responsive bnAb memory responses from genome-engineered human B cells in vivo, while also establishing the THX mouse as a physiologically relevant platform for HIV infection and treatment studies. Together, this work will provide a critical foundation for advancing engineered B cell vaccines as a potential functional cure for HIV.
Grant Summary
Establish HIV infection, treatment, and engineered B cell memory responses in the THX mouse model is a NIAID - National Institute of Allergy and Infectious Diseases grant providing up to $253K for university, nonprofit, healthcare org. Applications are due 2028-05-31 (open). Check eligibility and apply with FindGrants.
Focus Areas
Eligibility
How to Apply
Up to $253K
2028-05-31
- 1Confirm your organization is eligible for Establish HIV infection, treatment, and engineered B cell memory responses in the THX mouse model from NIAID - National Institute of Allergy and Infectious Diseases, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIAID - National Institute of Allergy and Infectious Diseases before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIAID - National Institute of Allergy and Infectious Diseases's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Establish HIV infection, treatment, and engineered B cell memory responses in the THX mouse model: Frequently Asked Questions
Who is eligible for the Establish HIV infection, treatment, and engineered B cell memory responses in the THX mouse model?
Establish HIV infection, treatment, and engineered B cell memory responses in the THX mouse model is offered by NIAID - National Institute of Allergy and Infectious Diseases and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Establish HIV infection, treatment, and engineered B cell memory responses in the THX mouse model provide?
Establish HIV infection, treatment, and engineered B cell memory responses in the THX mouse model provides up to $253K per award from NIAID - National Institute of Allergy and Infectious Diseases. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Establish HIV infection, treatment, and engineered B cell memory responses in the THX mouse model deadline?
Applications for Establish HIV infection, treatment, and engineered B cell memory responses in the THX mouse model are due 2028-05-31 (open). Because deadlines can change, verify the date with the funder, NIAID - National Institute of Allergy and Infectious Diseases, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Establish HIV infection, treatment, and engineered B cell memory responses in the THX mouse model?
To apply for Establish HIV infection, treatment, and engineered B cell memory responses in the THX mouse model, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIAID - National Institute of Allergy and Infectious Diseases.